Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Interferon regulatory factor 1: a key transcriptional node orchestrating macrophage polarization: mechanisms and therapeutic potential

  1. 1Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University

Abstract

Macrophageexhibit remarkable functional plasticity and adopt M1-like pro-inflammatory or M2-like anti-inflammatory/pro-resolving states in response to microenvironmental stimuli. Notably, this binary functional classification originates largely from in-vitro experimental systems; tissue-resident macrophages in vivo display a continuous spectrum of activation phenotypes rather than discrete subsets. Dysregulated macrophage polarization drives the pathogenesis of infectious diseases, malignancies, and metabolic-inflammatory disorders. Interferon regulatory factor 1 (IRF1) is a pivotal transcription factor governing macrophage fate, yet its multilayered regulatory circuits and context-dependent dual impacts on M1-like and M2-like transcriptional programs remain to be systematically summarized. This review synthesizes recent advances in IRF1-centered regulatory networks of macrophage polarization. We recapitulate IRF1 crosstalk with core signaling cascades including JAK/STAT, TLR/MyD88 and IFN-γ pathways, as well as its transcriptional control of target genes such as iNOS, IL-12, and CXCL10. Multi-layer regulatory mechanisms modulating IRF1 activity are outlined, including transcriptional, epigenetic, non-coding-RNA-mediated post-transcriptional, and post-translational modifications. We further dissect IRF1-linked immunometabolic reprogramming and epigenetic remodeling, and describe its versatile pathophysiological roles in infection, cancer and metabolic inflammatory diseases based on multi-omics and single-cell sequencing evidence. Collectively, this review illustrates IRF1 as a key transcriptional node that orchestrates macrophage polarization, and highlights prospective therapeutic targets and intervention strategies for IRF1-associated immune-mediated disorders.

Related

  1. Macrophage immunometabolism in osteoporosis: an emerging regulatory axis linking metabolic–polarization coupling to therapeutic targets
    Lian Weng, Qianli Yuan, Taizhou Mo +3
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  2. The role of interferon regulatory factors in atherosclerosis: from cell type-specific mechanisms to therapeutic strategies
    Jie Huang, Jia Wang, H H. Chen +2
    Frontiers in Cell and Developmental BiologyPeer-reviewedCC BY5 citedImmunologyOpenAlex
  3. BAP1 as a novel regulator of type I interferon signaling through transcriptional control of key response machinery components
    Yasaman Mortazavi, Hanyue Zhang, Robert Herrera +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  4. ATRX deficiency drives aberrant type I interferon signalling through cGAS-dependent transcriptional dysregulation
    Marie-Thérèse A. El-Daher, Eve L. White, Andreas Fellas +31
    Nature CommunicationsPeer-reviewedCC BY 4.0Full text2 citedImmunologyCrossrefEurope PMC
  5. Hippocampal interferon-response, unfolded-protein-response and synaptic transcriptional signatures in RORγt-transgenic mice
    T. Sasaki, S. Sanaka, K. Nakamura +3
    bioRxivPreprintCC BYFull textNeurosciencebioRxiv
BibTeX
@article{cao2026interferon,
  title = {{Interferon regulatory factor 1: a key transcriptional node orchestrating macrophage polarization: mechanisms and therapeutic potential}},
  author = {Shuqi Cao and Shuang Feng and Yue Gao and Zhiyuan Sun and Shiyao Bai and Xinming Su},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1884705},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1884705/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Interferon regulatory factor 1: a key transcriptional node orchestrating macrophage polarization: mechanisms and therapeutic potential
AU  - Shuqi Cao
AU  - Shuang Feng
AU  - Yue Gao
AU  - Zhiyuan Sun
AU  - Shiyao Bai
AU  - Xinming Su
PY  - 2026
DA  - 2026/10/21
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1884705
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1884705/full
AB  - Macrophageexhibit remarkable functional plasticity and adopt M1-like pro-inflammatory or M2-like anti-inflammatory/pro-resolving states in response to microenvironmental stimuli. Notably, this binary functional classification originates largely from in-vitro experimental systems; tissue-resident macrophages in vivo display a continuous spectrum of activation phenotypes rather than discrete subsets. Dysregulated macrophage polarization drives the pathogenesis of infectious diseases, malignancies, and metabolic-inflammatory disorders. Interferon regulatory factor 1 (IRF1) is a pivotal transcription factor governing macrophage fate, yet its multilayered regulatory circuits and context-dependent dual impacts on M1-like and M2-like transcriptional programs remain to be systematically summarized. This review synthesizes recent advances in IRF1-centered regulatory networks of macrophage polarization. We recapitulate IRF1 crosstalk with core signaling cascades including JAK/STAT, TLR/MyD88 and IFN-γ pathways, as well as its transcriptional control of target genes such as iNOS, IL-12, and CXCL10. Multi-layer regulatory mechanisms modulating IRF1 activity are outlined, including transcriptional, epigenetic, non-coding-RNA-mediated post-transcriptional, and post-translational modifications. We further dissect IRF1-linked immunometabolic reprogramming and epigenetic remodeling, and describe its versatile pathophysiological roles in infection, cancer and metabolic inflammatory diseases based on multi-omics and single-cell sequencing evidence. Collectively, this review illustrates IRF1 as a key transcriptional node that orchestrates macrophage polarization, and highlights prospective therapeutic targets and intervention strategies for IRF1-associated immune-mediated disorders.
SN  - 1664-3224
ER  -